prof. MUDr. Spyridon Gkalpakiotis, Ph.D.












            ******************************************************************************************

            *
            ******************************************************************************************
            <div class="skolitel"></div>

            Department of Dermatovenereology, Third Faculty of Medicine,
            Charles University and University hospital of Kralovske Vinohrady, Prague
            https://www.lf3.cuni.cz/3LF-998.html [ URL "https://www.lf3.cuni.cz/3LF-998.html"]


            Topic title
            Immunothrombosis - a new therapeutic target for the prevention of major cardiovascular eve

            with psoriasis?




            *=========================================================================================

            * Description of scientific activity
            *=========================================================================================
            Spyridon Gkalpakiotis graduated from the 3rd Faculty of Medicine, Charles University in Pr

            2005. After graduating, he joined the Department of Dermatovenerology, 3rd Faculty of Medi
            University and University hospital of Kralovske Vinohrady, where he is working till now. I
            defended his PhD degree on "Evaluation of the success of adjuvant melanoma therapy using r

            PCR". From 2013 he is the vice-chairman of the department and from December 2018 he has th
            associate professor at the 3rd Faculty of Medicine, Charles University where he teaches st
            general medicine and he is a supervisor for postgraduate students in the biomedicine progr

            publications in pubmed and his H-index is 9. In 2010, he received a gold award at the 22nd
            of Dermatology in Seoul, Korea, for the best poster describing the results of his disserta
            topic of circulating melanoma cells. At present, he specializes mainly in psoriasis, atopi

            and on biologic therapy. New insights in the pathophysiology of different inflammatory ski
            psoriasis and atopic dermatitis have introduced modern treatment modalities such as biolog
            Except from the progression in treatment of these diseases we today know, that the inflamm

            only on the skin but there is a systemic inflammation which has negative results in other 
            cardiovascular system. We have shown that patients with psoriasis have increased levels of
            systemic inflammation like IL-22, E-selectin and high sensitive CRP. Biologic therapy not 

            psoriasis on the skin but also decreases these markers which shows that has biologic thera
            the systemic inflammation. We have done research with anti TNF-a therapy, so one of the qu
            further investigation is if other biologics like anti IL-17 or anti IL-23 drugs could have

            One other project will be focusing on the prevention of cardiovascular events in patients 
            being treated with systemic therapy.






            *=========================================================================================
            * Selected publications
            *=========================================================================================

            Gkalpakiotis Spyridon; Arenbergerová Monika; Gkalpakioti Petra; Potočková Jana; Arenberger
            Pavel. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Resu
            study. The Journal of Dermatology. 2017, 44(4), 363-369. IF: 2.094/2016. <Poslední známý I


            Gkalpakiotis Spyridon; Arenbergerová Monika; Gkalpakioti Petra; Potočková Jana; Arenberger
            Pavel. Long Term Impact of Adalimumab Therapy on Biomarkers of Systemic Inflammation in Ps

            Results of a 2 year study. Dermatologic Therapy, 2020, 33(6): e14110. IF: 2.851/2020. <Pos
            2.851/2020>


            Torres Tiago; Puig Luis; Vender Ron; Lynde Charles; Piaserico Stefano; Carrascosa Jose M.;
            Paolo; Daudén Esteban; Conrad Curdin; Mendes-Bastos Pedro; Ferreira Paulo; Leite Luiz; Lu 
            Valerio J.; Bruni M.; Messina F.; Nidegger A.; Llamas-Velasco M.; Del Alcazar E.; Mufti A.

            Caldarola G.; Teixeira Laetitia; Romanelli Paolo; Desai K.; Gkalpakiotis Spyridon; Romanel
            Jensen; Nogueira Miguel; Chiricozzi Andrea. Drug Survival of IL-12/23, IL-17 and IL-23 Inh
            Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study, American Jo

            Dermatology, 2021, 22(4): 567-579. IF: 7.403/2020.< Poslední známý IF: 7.403/2020>




            *=========================================================================================
            * Selected or ongoing grants/clinical studies

            *=========================================================================================
            A PHASE 3B, MULTI CENTER, OPEN-LABEL LONGTERM EXTENSION STUDY OF APREMILAST (CC10004) IN P
            FROM 6 THROUGH 17 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS


            A randomized, subject and investigator blinded, placebo-controlled multicenter study to as
            and safety of CMK389 in patients with moderate to severe atopic dermatitis





            *=========================================================================================
            * PhD Students
            *=========================================================================================

            Number of current PhD students: 7
            Number of defended students with year of defense: 1 PhD (2019)